Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.45 EUR
Change Today +0.56 / 0.92%
Volume 0.0
JUD On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 10:59 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Open
€61.29
Previous Close
€60.89
Day High
€61.82
Day Low
€61.20
52 Week High
07/20/15 - €71.16
52 Week Low
10/15/14 - €44.00
Market Cap
17.3B
Average Volume 10 Days
106.0
EPS TTM
--
Shares Outstanding
281.7M
EX-Date
09/28/15
P/E TM
--
Dividend
€1.16
Dividend Yield
1.52%
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (JUD) Key Developments

St. Jude Medical, Inc. Announces Five Year Results from the Landmark FAME Trial

St. Jude Medical Inc. announced that five year results from the landmark FAME trial (Fractional Flow Reserve vs. Angiography in Multivessel Evaluation) have confirmed the long term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone. An analysis of the study’s five year follow up data confirms that in patients with multi-vessel coronary artery disease, FFR-guided PCI can contribute to reductions in all-cause mortality, cardiac mortality and an overall use of health care resources. The data, which were presented at the ESC Congress 2015, build upon previously-published results from the St. Jude Medical sponsored FAME trial at 12-months and two-year follow up intervals. After five years of patient follow up, FAME researchers have found that FFR guidance using St. Jude Medical PressureWire technology can lead to a more favorable treatment and clinical decision making, which can result in fewer events in the first two years and a sustained benefit up to five years. In addition, five year follow up data from the FAME trial demonstrate: improved patient outcomes, an overall decline in adverse events; and FFR’s positive economic impact on health care cost.

Abbott Laboratories Denies Report About Plans To Buy STJ Stake

Abbott Laboratories (NYSE:ABT) was rumored to be interested in acquiring a stake in St. Jude Medical Inc. (NYSE:STJ) (STJ). Share price of STJ gained to just more than 5%, after Marketwatch.com reported that Abbott Laboratories denied reports that it is pursuing a $25 billion bid to buy St. Jude Medical. The Financial Times earlier reported that Abbott Laboratories was planning to make a $25 billion bid for STJ, citing people familiar with the matter. The company is preparing an offer but has not yet put it forward, the paper had said.

St. Jude Medical, Inc., Enters into s 5-Year $2.6 billion Term Loan Facility and Multi-Year $1.5 billion Credit Agreement

On August 21, 2015, St. Jude Medical Inc., entered into a 5-year $2.6 billion term loan facility (the Term Facility) the terms of which are set forth in a term loan agreement, among St. Jude Medical, as borrower, Bank of America, N.A., as administrative agent and lender, and other lenders party thereto (the Term Loan Agreement). The Term Facility provides for up to $2.1 billion of term loans (under tranche 1 thereunder) to be used to finance a portion of the company's acquisition of Thoratec Corporation, a California corporation, and to pay fees and expenses related thereto. The Term Facility also provides for up to $500 million of term loans (under tranche 2 thereunder) to be used to refinance certain existing indebtedness of St. Jude Medical and for general corporate purposes. Upon entry into the Term Loan Agreement, the commitments under the Company's previously disclosed commitment letter with Bank of America, N.A. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, which was entered into on July 21, 2015, were automatically reduced by $2.1 billion. Any borrowings under tranche 1 or tranche 2 of the Term Facility will mature on the fifth anniversary of the closing date thereunder. Borrowings under the Term Facility will bear interest, at the election of the company, at a rate equal to LIBOR plus an applicable margin or the base rate plus an applicable margin, in each case subject to adjustment in the event of a change in the company's credit ratings. Also on August 21, 2015, St. Jude Medical entered into a Multi-Year $1.5 Billion Credit Agreement with a consortium of lenders (the Lenders) and Bank of America, N.A., as Administrative Agent, L/C Issuer and Lender. The Credit Agreement amends and re-states the Company's Multi-Year $1.5 Billion Credit Agreement dated as of May 31, 2013 among St. Jude Medical Inc., as the Borrower, Bank of America, N.A., as Administrative Agent, L/C Issuer and Lender, and the other Lenders party thereto (the Original Credit Agreement). The Credit Agreement creates a $1.5 billion unsecured revolving credit facility that the company can draw upon (i) to refinance certain existing indebtedness of the company, including amounts outstanding under the Original Credit Agreement and pay related fees and expenses and (ii) for general corporate purposes. The commitments under the Credit Agreement will expire on August 21, 2020. Borrowings under the Credit Agreement will initially bear interest at LIBOR plus 0.68%%, subject to adjustment in the event of a change in the company's credit ratings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €61.45 EUR +0.56

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.51 USD +0.42
CR Bard Inc $191.86 USD +4.31
Olympus Corp ¥4,115 JPY -60.00
Smith & Nephew PLC 1,136 GBp +6.00
Zimmer Biomet Holdings Inc $101.63 USD +0.98
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 19.1x
Price/Sales 3.5x
Price/Book 5.0x
Price/Cash Flow 17.1x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.